Evidence map›Paper›PMID 39916650›Full record

ArticleNanomedicine (London, England)2025

Aminofullerenes as targeted inhibitors of EGFR: from pancreatic cancer inhibitors to

Katarzyna Malarz, Julia Korzuch, Anna Mrozek-Wilczkiewicz, Magdalena Szubka, Patryk Rurka, Karol Małota, Aitor Herraiz, Dominik Dreszer, Karina Kocot, Fernando Herranz and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nanomedicine (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Katarzyna MalarzDepartment of Systems Biology and Engineering, Silesian University of Technology, Gliwice, Poland.
Julia KorzuchInstitute of Chemistry, Faculty of Science and Technology, University of Silesia in Katowice, Katowice, Poland.
Anna Mrozek-WilczkiewiczDepartment of Systems Biology and Engineering, Silesian University of Technology, Gliwice, Poland.
Magdalena SzubkaInstitute of Physics, Faculty of Science and Technology, University of Silesia in Katowice, Chorzów, Poland.
Patryk RurkaInstitute of Physics, Faculty of Science and Technology, University of Silesia in Katowice, Chorzów, Poland.
Karol MałotaInstitute of Biology, Biotechnology and Environmental Protection, Faculty of Natural Sciences, University of Silesia in Katowice, Katowice, Poland.
Aitor HerraizInstituto de Química Médica, Consejo Superior de Investigaciones Científicas (IQM-CSIC), Madrid, Spain.
Dominik DreszerInstitute of Chemistry, Faculty of Science and Technology, University of Silesia in Katowice, Katowice, Poland.
Karina KocotInstitute of Chemistry, Faculty of Science and Technology, University of Silesia in Katowice, Katowice, Poland.
Fernando HerranzInstituto de Química Médica, Consejo Superior de Investigaciones Científicas (IQM-CSIC), Madrid, Spain.
Magdalena Rost-RoszkowskaInstitute of Biology, Biotechnology and Environmental Protection, Faculty of Natural Sciences, University of Silesia in Katowice, Katowice, Poland.ORCID 0000-0001-7124-8423
Tao SunKey Laboratory of Smart Drug Delivery Ministry of Education, Department of Pharmaceutics, School of Pharmacy, Fudan University, Shanghai, China.
Robert MusiołInstitute of Chemistry, Faculty of Science and Technology, University of Silesia in Katowice, Katowice, Poland.
Maciej SerdaInstitute of Chemistry, Faculty of Science and Technology, University of Silesia in Katowice, Katowice, Poland.ORCID 0000-0003-4926-5782

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimPancreatic ductal adenocarcinoma (PDAC) is recognized as one of the most formidable cancers, largely due to its distinct microenvironment characterized predominantly by extensive desmoplastic stroma. In this study, we synthesized three novel water-soluble fullerene-based nanomaterials targeting EGFR protein.

methodsThe direct amination of fullerene carbon atoms, was followed by conjugation with a modified derivative of the EGFR inhibitor-erlotinib, resulting in the formation of novel water-soluble fullerene derivatives.

resultsFurther investigation into PAN02 and AsPC-1 cell lines revealed that these fullerene nanomaterials could induce cell cycle arrest in the G0/G1 phase, corroborated by alterations in the expression levels of the p27 and cyclin E1 proteins. Additionally, mechanisms of cell death were identified as autophagy for C

conclusionsCrucially, the study uncovered the efficacy of synthesized aminofullerenes in inhibiting the EGFR signaling pathway. The further toxicological studies of Gd@C

Indexed as

Antineoplastic AgentsCarcinoma, Pancreatic DuctalFullerenesPancreatic NeoplasmsAnimalsApoptosisAutophagyCell Line, TumorDrosophila melanogasterErbB ReceptorsErlotinib HydrochlorideHumansNanostructuresProtein Kinase InhibitorsSignal TransductionAntineoplastic AgentsEGFR protein, humanErbB ReceptorsErlotinib HydrochlorideFullerenesProtein Kinase Inhibitorsaminofullerenecancer nanotechnologydrosophilaEGFR inhibitorsFullerenepancreatic cancer

Identifiers

PMID39916650
PMCPMC11881853

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.